Cure My Disease

Don't miss your cure!

 Log in / Sign up

New nerve block could match standard for hip replacement pain

NCT ID NCT07683663

Symptom relief Sponsor: Dokuz Eylul University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This trial compares two types of nerve blocks given before hip replacement surgery to control pain afterward. One is the standard supra-inguinal fascia iliaca compartment block (SI-FICB), and the other is a newer quadro-iliac plane block (QIPB). The study includes adults aged 18-75 scheduled for elective hip replacement. Researchers measure pain scores at rest six hours after surgery to see if the newer block is at least as effective as the standard one.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bupivacaine
What this could lead to
If the newer block works as well as the standard one, patients may have another effective option for pain control after hip replacement.
What could go wrong
This is a small, early-stage comparison. The newer block may prove less effective or have unforeseen side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 84 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18-75 years * Scheduled for elective primary total hip arthroplasty * ASA physical status I-III * Able to understand and communicate in Turkish and complete assessment scales * Completed preoperative anesthesia evaluation and approved for surgery * Signed written informed consent Exclusion Criteria: * Known allergy/contraindication to any local anesthetic, including bupivacaine * Coagulopathy or anticoagulant/antiplatelet therapy contraindicating block (per ASRA 2022) * Active infection or skin breakdown at the block site * Chronic opioid use (≥3 months daily) or history of opioid dependence * Morbid obesity (BMI \> 40 kg/m²) * Cognitive impairment or communication difficulty precluding reliable NRS/QoR-15 assessment * Pregnancy or breastfeeding * Revision THA or emergency THA for fracture * Intraoperative complications requiring major protocol deviation (e.g., \>1000 mL blood loss, cardiac arrest) * Technically failed block (no sensory change at any region on the T1 cold test)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute pain are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Acute Pain osteoarthritis, hip Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute pain Hip osteoarthritis Postoperative pain Total hip arthroplasty (THA)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dokuz Eylül University

    Izmir, Balçova, 35340, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.